Comparison · NCT02610140-sae
Anetumab Ravtansine (BAY94-9343) vs Vinorelbine: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Anetumab Ravtansine (BAY94-9343) vs Vinorelbine: serious adverse events. Trial comparisons, record NCT02610140-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02610140-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.344 | 0.275 | 0.419 | wilson | |
| Risk in group 2 | 0.347 | 0.248 | 0.462 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00366 | -0.138 | 0.122 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.989 | 0.676 | 1.45 | log | |
| Odds ratio, group 1 over group 2 | 0.984 | 0.549 | 1.76 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Anetumab Ravtansine (BAY94-9343) than on Vinorelbine | 273 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Anetumab Ravtansine (BAY94-9343) | Test drug: 6.5 mg/kg every 3 weeks; Intravenous (IV) infusion over 1 hour | 56 | 163 | EG000 |
| Group 2 | Vinorelbine | Active comparator: 30 mg/m\^2 once weekly | 25 | 72 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to approx. 55 months (data cut-off: 02-Jul-2019) - Time from randomization until 30 days after last treatment (general AEs), or further until death from any cause (selected AEs).
Source ClinicalTrials.gov
Trial
- Title
- Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
- NCT number
- NCT02610140
- Phases
- PHASE2
- Conditions
- Mesothelioma
- Interventions
- Anetumab ravtansine (BAY94-9343), Vinorelbine
- Lead sponsor
- Bayer
- Results first posted
- 2020-07-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02610140?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02610140-sae